Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

HIV antigen variability in ARC/AIDS.

C W Hendrix1, P A Volberding, R E Chaisson

  • 1Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205.

Journal of Acquired Immune Deficiency Syndromes
|January 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Body mass index and the risk of TB.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2026
Same author

Stakeholder engagement to identify barriers to implementation and inform the development of point-of-care diagnostics for TB.

IJTLD open·2026
Same author

Safety, Pharmacokinetics, and Acceptability of a Tenofovir Rectal Microbicide Douche Among Young Men Who Have Sex With Men: The DREAM ATN Study (ATN 163).

The Journal of infectious diseases·2025
Same author

Reply to Authors: addressing concerns to ensure effective TB preventive therapy.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2025
Same author

Assessing TB treatment outcomes in pregnant women living with HIV with drug-susceptible TB.

Public health action·2025
Same author

Person-centred language for describing stratified approaches to TB treatment.

IJTLD open·2025
Same journal

T lymphocyte homeostasis after HIV seroconversion.

Journal of acquired immune deficiency syndromes·1994
Same journal

Improved detection of HTLV-II antibody using a whole viral lysate-based EIA.

Journal of acquired immune deficiency syndromes·1994
Same journal

Changes in HIV risk behavior among French heterosexuals: patterns of sexual monogamy and condom use between 1988 and 1991.

Journal of acquired immune deficiency syndromes·1994
Same journal

HTLV-I-associated myelopathy in Venezuela.

Journal of acquired immune deficiency syndromes·1994
Same journal

Autoantibodies to nucleosomes in HIV-1-infected patients.

Journal of acquired immune deficiency syndromes·1994
Same journal

Seroprevalence of HIV-1 and syphilis antibodies in blood donors in Gonder, Ethiopia, 1989-1993.

Journal of acquired immune deficiency syndromes·1994
See all related articles

Human immunodeficiency virus p24 antigen (HIV Ag) shows significant natural variability in untreated patients. This broad HIV Ag variability is crucial for designing clinical trials of antiviral therapies.

Area of Science:

  • Virology
  • Immunology
  • Clinical Trials

Background:

  • Human immunodeficiency virus (HIV) p24 antigen (Ag) is a key marker in HIV infection.
  • Understanding natural antigen variability is essential for interpreting treatment efficacy in clinical trials.

Purpose of the Study:

  • To quantify the natural variability of serum HIV p24 antigen over time in untreated HIV-infected individuals.
  • To inform the design of clinical trials using HIV p24 antigen as a surrogate marker.

Main Methods:

  • Analysis of serum HIV p24 antigen percentage change in 40 antigenemic subjects on placebo over 24 weeks.
  • Statistical evaluation of HIV Ag changes across different observation periods (1-5 months).
  • Correlation analysis between HIV p24 antigen and CD4 T-cell changes.

Related Experiment Videos

Main Results:

  • No significant differences in HIV p24 antigen change were observed across monthly or longer observation periods (p > 0.4).
  • The mean monthly HIV p24 antigen change was 0%, with substantial standard deviations (77% increase, 44% decrease).
  • HIV p24 antigen changes did not correlate with CD4 T-cell changes.

Conclusions:

  • Significant natural variability exists in HIV p24 antigen levels in untreated HIV infection.
  • This variability must be considered when calculating sample sizes and defining endpoints in clinical trials.
  • Accurate understanding of HIV p24 antigen variability enhances the reliability of surrogate markers in antiviral drug efficacy studies.